GSK, Novartis agree to $4.5M penalty for misleading Osteo Gel claims

Competition & Consumer Protection 2020-05-04 3:40 pm By Alison Eveleigh | Sydney

GlaxoSmithKline and Novartis have agreed to a combined penalty of $4.5 million after the Australian Competition and Consumer Commission accused the pharmaceutical giants of making misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.